Inside the Innovation CLOSE × Welcome Some content on this site is not intended for people outside the United States. ACCEPT Cookie Notice We use cookies to offer you a better browsing experience, analyze site traffic, personalize content, and serve targeted advertisements. Read about how we use cookies and how you can control them byclicking here. Cookies Settings Disable Cookies Accept All Cookies

Events Stories Newsroom Company Statements Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Company Statements Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Foster City, Calif. & Kenilworth, N.J.- November 23, 2021 - Gilead Sciences, Inc. and Merck, known as MSD outside the United States and Canada, are temporarily pausing enrollment in the Phase 2 clinical study (), evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy. This temporary pause has been implemented out of an abundance of caution, to allow the companies to consider potential protocol adjustments to the trial in light of Merck’s announcement on November 18 regarding the decision to stop dosing in the Phase 2 IMAGINE-DR clinical trial (evaluating the once-weekly combination of MK-8507 and islatravir. The companies remain optimistic about the future potential of the islatravir and lenacapavir combination regimen to provide a once-weekly oral therapy option for people living with HIV. Cookie Notice We use cookies to offer you a better browsing experience, analyze site traffic, personalize content, and serve targeted advertisements. Read about how we use cookies and how you can control them byclicking here. Cookies Settings Disable Cookies Accept All Cookies

Leadership U.S. Locations How We Operate Ethics and Code of Conduct Policies Disclosures Supplier Information Gilead uses its scientific expertise to help transform and simplify care for people with life-threatening illnesses around the world. With a portfolio of more than 25 products and hundreds of ongoing and planned clinical studies, we are focused on solving some of the biggest health challenges today. For more than 30 years, Gilead’s products have targeted therapeutic areas of unmet medical need, which today include HIV/AIDS, liver diseases, hematology and oncology, cell therapy, inflammatory diseases and respiratory diseases. To learn more, visit Gilead’s 2020 Year in Review. Cookie Notice We use cookies to offer you a better browsing experience, analyze site traffic, personalize content, and serve targeted advertisements. Read about how we use cookies and how you can control them byclicking here. Cookies Settings Disable Cookies Accept All Cookies